Natural Capsules

Why is Natural Capsules Ltd falling/rising?

As of 11-Aug, the stock price of Natural Capsules Ltd is currently at 166.15, reflecting a decline after three days of gains and underperforming its sector. Despite increased investor participation, the stock shows a year-to-date decline of 0.87% and a significant drop of 22.05% over the past year.

As of 11-Aug, the stock price of Natural Capsules Ltd is falling, currently at 166.15, which reflects a change of -2.3 or -1.37%. This decline comes after a trend reversal, as the stock has fallen following three consecutive days of gains. Additionally, the stock has underperformed its sector by 2.08% today. <BR><BR>Intraday, the stock reached a low of Rs 160.05, marking a significant drop of 4.99%. The weighted average price indicates that more volume was traded closer to this low price, suggesting a lack of buying interest at higher levels. Although the stock's moving averages are higher than the 5-day, 20-day, 50-day, and 100-day averages, it remains lower than the 200-day moving average, which could indicate a longer-term bearish trend.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 11% against the 5-day average, the overall performance year-to-date shows a decline of 0.87%, and over the past year, the stock has decreased by 22.05%. These factors collectively contribute to the current downward movement in the stock price of Natural Capsules Ltd.

Which are the latest news on Natural Capsules?

When is the next results date for Natural Capsules Ltd?

The next results date for Natural Capsules Ltd is 12 August 2026.

The next results date for Natural Capsules Ltd is scheduled for 12 August 2026.

How big is Natural Capsules?

As of 10th June, Natural Capsules Ltd has a market capitalization of 162.00 Cr and reported net sales of 187.20 Cr with a loss of 20.95 Cr over the latest four quarters. Shareholder's funds are 232.94 Cr, and total assets are valued at 419.35 Cr.

As of 10th June, Natural Capsules Ltd has a market capitalization of 162.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Natural Capsules reported net sales of 187.20 Cr. However, the company experienced a loss of 20.95 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's funds stand at 232.94 Cr, while total assets are valued at 419.35 Cr.

Who are in the management team of Natural Capsules?

The management team of Natural Capsules includes Laxminarayan Moondra, Satyanarayan Mundra, C P Rangachar, Sunil L Mundra, Sushil Kumar Mundra, Jyothi Mundra, Pramod Kasat, Shilpa Burman, and Shirish Gundopant Belapure, who oversee the company's operations and strategic direction.

The management team of Natural Capsules includes the following key individuals:<BR><BR>1. **Laxminarayan Moondra** - Whole-time Director<BR>2. **Satyanarayan Mundra** - Whole-time Director<BR>3. **C P Rangachar** - Chairman & Independent Director<BR>4. **Sunil L Mundra** - Managing Director<BR>5. **Sushil Kumar Mundra** - Director<BR>6. **Jyothi Mundra** - Director<BR>7. **Pramod Kasat** - Independent Director<BR>8. **Shilpa Burman** - Company Secretary & Compliance Officer<BR>9. **Shirish Gundopant Belapure** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Natural Capsules?

Natural Capsules' peers include Oxygenta Pharma, Coral Labs, Sanjiv.Parant, Auro Labs, Achyut Healthcar, Panch.Organics, and Quest Laborato. In terms of management risk, growth, and capital structure, Natural Capsules ranks below average compared to its peers.

Peers: The peers of Natural Capsules are Oxygenta Pharma, Coral Labs., Sanjiv.Parant., Auro Labs., Achyut Healthcar, Panch.Organics, and Quest Laborato.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Quest Laborato., while Average management risk is found at Auro Labs. and Panch.Organics, and Below Average management risk is noted at Coral Labs., Achyut Healthcar, and Natural Capsules. For Growth, Good growth is seen at Sanjiv.Parant. and Quest Laborato., Average growth is noted at Achyut Healthcar, while Below Average growth is found at Coral Labs., Auro Labs., Natural Capsules, and the rest. In terms of Capital Structure, Excellent capital structure is held by Coral Labs. and Panch.Organics, Good capital structure is seen at Sanjiv.Parant. and Achyut Healthcar, while Average capital structure is noted at Auro Labs. and Below Average at Natural Capsules and Oxygenta Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Guj. Inject(Ker) at 425.37%, while Oxygenta Pharma has the lowest at -60.96%. Natural Capsules' 1-year return of -35.45% is better than Oxygenta Pharma's but worse than Guj. Inject(Ker). Additionally, the peers with negative six-month returns include Oxygenta Pharma, Auro Labs., Natural Capsules, and Panch.Organics.

What does Natural Capsules do?

Natural Capsules Ltd is a micro-cap manufacturer of hard capsule shells, specializing in vegetarian and gelatin capsules, with a market cap of INR 162 Cr. As of March 2026, it reported net sales of 58 Cr and a net loss of 3 Cr.

Overview:<BR>Natural Capsules Ltd is a leading manufacturer of hard capsule shells in the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in 1993, Natural Capsules Ltd has established itself as a prominent player in the market, introducing vegetarian capsules to India and becoming the second-largest manufacturer of gelatin capsules in the country. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 58 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: -3 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 162 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.50<BR>- Return on Equity: -9.45%<BR>- Price to Book: 0.75<BR><BR>Contact Details:<BR>Address: Trident Towers 4th Floor No 23, 100Feet Road Jayanagar II Block Bangalore Karnataka : 560011<BR>Tel: 91-080-26671571/26671573/26671581<BR>Email: company.sec@naturalcapsules.com<BR>Website: http://www.naturalcapsules.com

Should I buy, sell or hold Natural Capsules Ltd?

Are Natural Capsules Ltd latest results good or bad?

Natural Capsules Ltd's latest results are concerning, showing a net loss of ₹6.99 crores for Q2 FY26, a significant decline from last year's profit, despite an 11.11% revenue increase. The company's operating margin is at -1.94%, and the stock has dropped 4.66% post-announcement, indicating serious financial challenges and a "STRONG SELL" rating.

Natural Capsules Ltd's latest results are concerning and indicate a significant decline in financial health. The company reported a net loss of ₹6.99 crores for Q2 FY26, which is a drastic increase in losses compared to the same quarter last year, where they had a positive net profit. Although revenue increased by 11.11% year-on-year to ₹45.80 crores, this growth is overshadowed by severe margin compression, leading to an operating margin of -1.94%, the lowest in seven quarters.<BR><BR>The stock price has reacted negatively, plummeting 4.66% to ₹195.50 following the results announcement, and it has experienced a year-to-date decline of 27.99%. The company's performance has significantly underperformed the broader market, with a Mojo Score of just 23 out of 100 and a "STRONG SELL" rating.<BR><BR>Overall, the results reflect a company struggling with operational inefficiencies and rising costs, which have led to a critical financial situation. The outlook appears bleak, with multiple red flags indicating that investors should approach with caution.

Is Natural Capsules overvalued or undervalued?

As of November 14, 2025, Natural Capsules is considered overvalued and risky, with concerning financial metrics such as a PE ratio of -16.93 and an EV to EBITDA of 37.39, significantly underperforming compared to competitors like Sun Pharma and Cipla, and reflecting a negative stock performance of -28.65% over the past year.

As of 14 November 2025, the valuation grade for Natural Capsules has moved from expensive to risky, indicating a significant shift in the company's perceived value. Based on the analysis, Natural Capsules is currently considered overvalued. The company displays a PE ratio of -16.93, an EV to EBITDA of 37.39, and a Price to Book Value of 0.87, which are concerning metrics compared to its peers.<BR><BR>In comparison to notable competitors, Sun Pharma has a PE ratio of 36.49 and an EV to EBITDA of 24.09, while Cipla maintains a more attractive PE ratio of 22.72 and an EV to EBITDA of 16.08. These ratios highlight that Natural Capsules is not only underperforming relative to its peers but also suggests a lack of investor confidence reflected in its negative stock performance over the past year, with a return of -28.65% compared to a 9.00% gain in the Sensex.

How has been the historical performance of Natural Capsules?

Natural Capsules experienced fluctuating financial performance, with net sales increasing to 169.21 Cr in March 2025 but a decline in profitability, as profit after tax fell to 0.62 Cr. Total assets grew to 419.35 Cr, indicating growth in sales and assets despite challenges in profitability.

Answer:<BR>The historical performance of Natural Capsules shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Natural Capsules reported net sales of 169.21 Cr in March 2025, an increase from 155.42 Cr in March 2024, but a decrease from 172.37 Cr in March 2023. The total operating income followed a similar pattern, reaching 169.21 Cr in March 2025. Raw material costs rose to 86.88 Cr in March 2025 from 84.00 Cr in March 2024, while total expenditure increased to 151.69 Cr in March 2025. Operating profit (PBDIT) decreased to 18.22 Cr in March 2025 from 21.86 Cr in March 2024, leading to a profit before tax of 2.79 Cr in March 2025, down from 8.05 Cr the previous year. The profit after tax also fell to 0.62 Cr in March 2025 from 5.55 Cr in March 2024. Total assets grew to 419.35 Cr in March 2025, up from 376.53 Cr in March 2024, while total liabilities also increased to 419.35 Cr. Cash flow from operating activities showed a positive trend with 26.00 Cr in March 2025, compared to -8.00 Cr in March 2024. Overall, the company's financial performance reflects both growth in sales and assets, but challenges in profitability in the most recent year.

Who are the top shareholders of the Natural Capsules?

The top shareholders of Natural Capsules include Tajos Investments Private Limited with 12.12%, followed by Tarinika Management LLP at 3.22%, and individual investors holding a collective 33.09%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Natural Capsules are primarily the promoters, with Tajos Investments Private Limited holding the highest stake at 12.12%. In terms of public shareholders, Tarinika Management LLP is the largest, owning 3.22%. Additionally, individual investors collectively hold 33.09% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

What is the technical trend for Natural Capsules?

As of June 4, 2025, Natural Capsules show a neutral technical stance with mixed signals: mildly bullish weekly indicators contrast with bearish monthly trends.

As of 4 June 2025, the technical trend for Natural Capsules has changed from mildly bearish to sideways. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The weekly Bollinger Bands are bullish, contrasting with the monthly which is mildly bearish. Daily moving averages show a mildly bearish trend. The KST is mildly bullish on the weekly but bearish on the monthly, and Dow Theory supports a mildly bullish view on both weekly and monthly time frames. The OBV is bullish for both weekly and monthly periods. Overall, the current technical stance is neutral, with mixed signals across different indicators.

Has Natural Capsules declared dividend?

Natural Capsules Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 20, 2023. Despite the dividend declaration, the company has experienced negative total returns in the short to medium term, but has shown strong recovery over the longer 4 to 5-year periods.

Natural Capsules Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.79%, with a dividend return of 0%, resulting in a total return of -13.79%.<BR><BR>Over the past year, the price return was -10.27%, with a dividend return of 0%, leading to a total return of -10.27%.<BR><BR>In the 2-year period, the price return was -26.91%, with a dividend return of 0.27%, culminating in a total return of -26.64%.<BR><BR>For the 3-year period, the price return was -44.67%, with a dividend return of 0.50%, resulting in a total return of -44.17%.<BR><BR>In the 4-year period, the price return was 63.49%, with a dividend return of 2.01%, leading to a total return of 65.5%.<BR><BR>Over the last 5 years, the price return was 432.19%, with a dividend return of 7.21%, resulting in a total return of 439.4%.<BR><BR>Overall, while Natural Capsules Ltd has declared a dividend, the recent total returns indicate a mixed performance, with significant declines in the short to medium term, but a strong recovery over the longer 4 to 5-year periods.